MX2020003844A - Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. - Google Patents
Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica.Info
- Publication number
- MX2020003844A MX2020003844A MX2020003844A MX2020003844A MX2020003844A MX 2020003844 A MX2020003844 A MX 2020003844A MX 2020003844 A MX2020003844 A MX 2020003844A MX 2020003844 A MX2020003844 A MX 2020003844A MX 2020003844 A MX2020003844 A MX 2020003844A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- nervous system
- decline
- central nervous
- treatment
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 230000007423 decrease Effects 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000009109 curative therapy Methods 0.000 title abstract 2
- 230000007996 neuronal plasticity Effects 0.000 title abstract 2
- 230000003449 preventive effect Effects 0.000 title abstract 2
- 230000003956 synaptic plasticity Effects 0.000 title abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- CXJAAWRLVGAKDV-UHFFFAOYSA-M acetyltaurine(1-) Chemical compound CC(=O)NCCS([O-])(=O)=O CXJAAWRLVGAKDV-UHFFFAOYSA-M 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000008447 perception Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular una disminución de la plasticidad sináptica, por ejemplo, en el tratamiento de enfermedades del sistema nervioso central que afectan a procesos cognitivos tales como el aprendizaje, la percepción, la atención, el razonamiento, el lenguaje y/o la memoria, en el tratamiento de enfermedades del sistema nervioso central tales como enfermedades neurodegenerativas que incluyen la enfermedad de Parkinson, la enfermedad de Alzheimer y/o la esclerosis lateral amiotrófica, en el tratamiento de enfermedades del sistema nervioso central responsables de los trastornos del estado de ánimo, la hiperexcitabilidad, la hiperactividad y/o el estrés, y en el tratamiento de condiciones neurológicas tales como la epilepsia, dicho compuesto siendo N-acetil taurinato de magnesio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE2017/5731A BE1025644B1 (fr) | 2017-10-13 | 2017-10-13 | Compose pour le traitement d'une maladie ou d'un trouble du systeme nerveux central chez un sujet en stimulant et/ou en restaurant la plasticite neuronale |
| PCT/EP2018/076133 WO2019072568A1 (fr) | 2017-10-13 | 2018-09-26 | Composé et composition pour utilisation dans le traitement préventif et/ou curatif des maladies du système nerveux central caractérisées par un déclin de la plasticité neuronale, en particulier caractérisées par un déclin de la plasticité synaptique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003844A true MX2020003844A (es) | 2020-11-06 |
Family
ID=60164541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003844A MX2020003844A (es) | 2017-10-13 | 2018-09-26 | Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200237812A1 (es) |
| EP (1) | EP3694505B1 (es) |
| CN (1) | CN111315373A (es) |
| BE (1) | BE1025644B1 (es) |
| BR (1) | BR112020007341A2 (es) |
| CA (1) | CA3079410A1 (es) |
| DK (1) | DK3694505T3 (es) |
| ES (1) | ES2965493T3 (es) |
| FI (1) | FI3694505T3 (es) |
| MX (1) | MX2020003844A (es) |
| PL (1) | PL3694505T3 (es) |
| PT (1) | PT3694505T (es) |
| SI (1) | SI3694505T1 (es) |
| WO (1) | WO2019072568A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021013851A (es) | 2019-05-16 | 2022-01-07 | Synapharm Ind Synthesis | Compuesto y composicion para el uso en el tratamiento del sindrome premenstrual y/o trastorno disforico premenstrual. |
| US11376277B2 (en) | 2020-06-01 | 2022-07-05 | Celagenex Research (India) Pvt. Ltd. | Synergistic medicinal compositions for treating dysfunctional D-serine signaling |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2384751A1 (fr) * | 1977-03-23 | 1978-10-20 | Francaise Coop Pharma | Nouveaux derives de la taurine a activite neuro-musculaire renforcee |
| IT1237435B (it) | 1989-12-14 | 1993-06-04 | Farmaco attivo nel ripristino della plasticita' neuronale. | |
| FR2704391B1 (fr) * | 1993-04-27 | 1995-06-02 | Boiron | Complément nutritionnel absorbable pour faciliter l'adaptation au stress quodidien. |
| US7148192B2 (en) * | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
| CA2637786A1 (en) | 2006-01-23 | 2007-08-16 | President And Fellows Of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
| US20080249178A1 (en) * | 2007-03-22 | 2008-10-09 | Guosong Liu | Magnesium compositions and uses thereof for increasing lifespan |
| BRPI0809103B8 (pt) * | 2007-03-22 | 2021-05-25 | Neurocentria Inc | composição contendo magnésio, seu uso e composição de alimento |
| US20110072525A1 (en) * | 2009-09-22 | 2011-03-24 | Effat Emamian | Compositions and methods for the treatment of psychiatric and neurological disorders |
| WO2011041451A2 (en) * | 2009-09-30 | 2011-04-07 | Harlan Clayton Bieley | Smoking cessation with body weight maintenance and nutritional supplement |
| FI129157B (en) * | 2012-05-28 | 2021-08-13 | Biohit Oyj | Composition for use in reducing the incidence of or preventing severe headaches |
| JP2016514673A (ja) * | 2013-03-15 | 2016-05-23 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | 改善された認知機能サプリメント |
| EA201790017A1 (ru) * | 2014-06-24 | 2017-06-30 | Дедраф Холдинг Б.В. | Новая минеральная композиция |
-
2017
- 2017-10-13 BE BE2017/5731A patent/BE1025644B1/fr active IP Right Grant
-
2018
- 2018-09-26 US US16/754,994 patent/US20200237812A1/en not_active Abandoned
- 2018-09-26 PL PL18773776.2T patent/PL3694505T3/pl unknown
- 2018-09-26 CN CN201880072217.XA patent/CN111315373A/zh active Pending
- 2018-09-26 WO PCT/EP2018/076133 patent/WO2019072568A1/fr not_active Ceased
- 2018-09-26 FI FIEP18773776.2T patent/FI3694505T3/fi active
- 2018-09-26 PT PT187737762T patent/PT3694505T/pt unknown
- 2018-09-26 SI SI201831020T patent/SI3694505T1/sl unknown
- 2018-09-26 EP EP18773776.2A patent/EP3694505B1/fr active Active
- 2018-09-26 DK DK18773776.2T patent/DK3694505T3/da active
- 2018-09-26 MX MX2020003844A patent/MX2020003844A/es unknown
- 2018-09-26 ES ES18773776T patent/ES2965493T3/es active Active
- 2018-09-26 CA CA3079410A patent/CA3079410A1/en active Pending
- 2018-09-26 BR BR112020007341-5A patent/BR112020007341A2/pt unknown
-
2021
- 2021-09-22 US US17/482,003 patent/US20220008455A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI3694505T1 (sl) | 2024-02-29 |
| US20220008455A1 (en) | 2022-01-13 |
| FI3694505T3 (fi) | 2023-12-20 |
| PL3694505T3 (pl) | 2024-04-02 |
| US20200237812A1 (en) | 2020-07-30 |
| WO2019072568A1 (fr) | 2019-04-18 |
| BR112020007341A2 (pt) | 2020-10-06 |
| DK3694505T3 (da) | 2024-01-02 |
| PT3694505T (pt) | 2023-12-05 |
| BE1025644B1 (fr) | 2019-05-15 |
| EP3694505B1 (fr) | 2023-10-04 |
| ES2965493T3 (es) | 2024-04-15 |
| BE1025644A1 (fr) | 2019-05-10 |
| CA3079410A1 (en) | 2019-04-18 |
| CN111315373A (zh) | 2020-06-19 |
| EP3694505A1 (fr) | 2020-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| ECSP19021843A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| CO2018002822A2 (es) | Compuestos deuterados y usos de los mismos | |
| MX2018010693A (es) | Compuestos biciclicos para diagnostico y terapia. | |
| BR112018068538A2 (pt) | composto, medicamento, uso de um composto, e, métodos para inibir monoacilglicerol lipase e para profilaxia ou tratamento de doença ou transtorno. | |
| DOP2016000195A (es) | Compuestos | |
| CO2020002992A2 (es) | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides | |
| MX2016010409A (es) | Combinacion de baclofeno, acamprosato y trigliceridos de cadena media para el tratamiento de trastornos neurologicos. | |
| MX2017015752A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| IN2013DN11328A (es) | ||
| MX2016007803A (es) | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. | |
| MX2020003844A (es) | Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. | |
| MX2019013524A (es) | Composiciones para tratar enfermedades neurodegenerativas. | |
| MX2020005952A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| BR112015015509A2 (pt) | composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal | |
| MX2020008138A (es) | Formulaciones parentales y usos de estas. | |
| CL2018003113A1 (es) | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular. | |
| MX2016016118A (es) | Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo. | |
| BR112019006429A2 (pt) | composição compreendendo combinação de análogo de trh com ácido arúndico, e sal farmaceuticamente aceitável de ácido arúndico | |
| BR112018012343A2 (pt) | composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos | |
| MX2022013029A (es) | Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos. | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease |